文献速递临床试验与 GCP

当归芍药散治疗围绝经期及绝经后血虚型更年期综合征:随机双盲安慰剂对照预试验方案

Danggwijagyaksan for climacteric syndrome in peri- and postmenopausal women with a blood-deficiency dominant pattern: study protocol for a randomized, double-blind, placebo-controlled pilot trial.
PubMed 文献 · Trials · 2018-01-15

本研究为随机、双盲、安慰剂对照预试验,计划纳入34名签署知情同意书、血虚型为主的围绝经期及绝经后更年期综合征女性,按等比例随机分配接受安慰剂或当归芍药散(DJS)颗粒,治疗4周、每日三次。主要结局为第5周更年期评定量表评分较基线的平均变化,次要结局包括WHOQOL-BREF评分、血虚评分系统评分、瘦体重及血清促卵泡激素和雌二醇等,并评估安全性与可行性。

要点

  • 计划纳入34名血虚型为主的围绝经期及绝经后更年期综合征女性,等比例随机接受安慰剂或DJS颗粒。
  • 治疗期4周、每日三次,主要结局为第5周更年期评定量表评分较基线的平均变化。
  • 安全性通过治疗前后实验室检查及每次访视时询问不良事件评估,并计算招募率、完成率和服药依从性以评估可行性。

核心结论

  • 本研究旨在探索DJS缓解血虚型为主围绝经期及绝经后女性更年期综合征的安全性、疗效与可行性。
  • 研究结果将为确认DJS治疗更年期综合征安全性和疗效的全规模随机对照试验提供依据。

研究设计与样本

  • 随机、双盲、安慰剂对照预临床试验。
  • 计划登记34名签署知情同意书的更年期综合征女性,按等比例随机分配接受安慰剂或DJS。
  • 参与者每2周访视临床 trial 中心并接受安慰剂或DJS颗粒,治疗期4周、每日三次。
  • 于基线、随机分配后第5周和第9周收集数据。

主要发现

  • 主要结局指标为更年期评定量表评分从基线至第5周的平均变化。
  • 次要结局指标包括WHOQOL-BREF评分、血虚评分系统评分、瘦体重及包括血清促卵泡激素和雌二醇浓度在内的血液检查。
  • 通过治疗前后实验室检查及每次访视询问不良事件评估DJS安全性。
  • 计算招募率、完成率和服药依从性以评估可行性。

关键数值与推荐

  • 治疗期4周,给药频率为每日三次。
  • 主要结局为更年期评定量表评分从基线至第5周的平均变化。
  • 次要结局包括WHOQOL-BREF评分、血虚评分系统评分、瘦体重、血清促卵泡激素和雌二醇浓度。
  • 数据收集时点为基线、随机分配后第5周和第9周。

临床怎么用

  • 本研究为预试验方案,结果将用于为全规模随机对照试验提供依据。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aims to explore the safety, efficacy, and feasibility of Danggwijagyaksan (DJS) for alleviating climacteric syndrome in peri- and postmenopausal women with a blood-deficiency dominant pattern. METHODS/DESIGN: This is a randomized, double-blind, placebo-controlled pilot clinical trial. A total of 34 women with climacteric syndrome who have signed informed consent forms will be registered in this study. Placebo or DJS will be randomly assigned to the participants in an equal proportion. The participants will visit the clinical trial center every 2 weeks and receive placebo or DJS granules. The treatment period is 4 weeks and the administration frequency is three times daily. Data will be collected from the participants at baseline, at week 5, and at week 9 after random allocation. The primary outcome measure will be the mean change in the Menopause Rating Scale from baseline to week 5. Secondary outcome measures will include the World Health Organization Quality of Life-BREF (WHOQOL-BREF) score, the Blood Deficiency Scoring System score, lean body mass, and blood tests, including serum follicle-stimulating hormone and estradiol concentration. To assess the safety of DJS, a laboratory test will be conducted before and after treatment and the participants will be asked about any occurrence of adverse events every visit. The recruitment rate, completion rate, and medication adherence will also be calculated, to assess feasibility. DISCUSSION: The findings of this study will provide the basis for a full-scale randomized controlled trial to confirm the safety and efficacy of DJS for the treatment of climacteric syndrome in peri- and postmenopausal women. TRIAL REGISTRATION: Clinical Research Information Service (CRIS), Republic of Korea, KCT0002387 . Registered on 25 July 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kim M, Kim AR, Park HJ, et al. Danggwijagyaksan for climacteric syndrome in peri- and postmenopausal women with a blood-deficiency dominant pattern: study protocol for a randomized, double-blind, placebo-controlled pilot trial. Trials. 2018. PMID: 29335018. doi:10.1186/s13063-018-2443-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。